CD274 and breast carcinoma: Co-expression of these molecules with PD-1 often marks deeply dysfunctional T-cell populations in NSCLC, breast cancer and esophageal cancer, and preclinical studies suggest that dual or triple blockade can further invigorate immune responses against tumors that are recalcitrant to PD-1/PD-L1 monotherapy.